Connect with us

Science

Researcher Develops Innovative Tool for Early Cancer Detection

Editorial

Published

on

A childhood experience with a friend’s illness has inspired Dr. Judy Ann Cocadiz, a researcher from the University of Otago, to pursue groundbreaking cancer research. With the support of a three-year, $300,000 post-doctoral fellowship from the Cancer Society’s 2025 National Research Grant Round, she aims to develop a tool that could revolutionise early-stage cancer diagnosis.

Cocadiz’s research focuses on circulating tumour DNA (ctDNA), which consists of DNA fragments released into the bloodstream by cancer cells. The concentration of ctDNA typically increases with the advancement of cancer, making it a promising biomarker for diagnosis. Currently, ctDNA is identified through blood samples, but the process has limitations, particularly for early-stage cancers where ctDNA levels are minimal.

Innovative Device Aims to Improve Detection

Cocadiz is working on a novel device designed to be inserted into a blood vessel, functioning as a “sieve” to capture ctDNA efficiently. This method allows for a short collection period, potentially enabling doctors to identify cancer at earlier stages and monitor for recurrence post-treatment. “Typically, we draw about 8-10 ml of blood to analyse ctDNA,” Cocadiz explained. “The challenge is that in early-stage cancer, the ctDNA concentration is so low, it’s akin to searching for a needle in a haystack.”

To mitigate the discomfort associated with conventional blood draws, particularly in vulnerable populations such as children and the elderly, Cocadiz’s device aims to collect ctDNA without the need for larger blood samples. “Instead of needing to take more blood, our device can be inserted, collect ctDNA for a few minutes, and then be removed,” she noted. This innovation not only promises to enhance diagnostic accuracy but also to reduce patient discomfort.

Though still in the proof-of-concept stage, Cocadiz envisions the device operating similarly to an intravenous (IV) line, inserted into a patient’s vein in a manner akin to that of a standard needle. While bringing this technology to clinical use will take time, Cocadiz expressed optimism about the direction of her research.

A Personal Journey into Cancer Research

Cocadiz’s passion for cancer research was ignited during her childhood in the Philippines. At just five years old, she noticed that her best friend frequently had large bruises from minor accidents. Concerned, she informed her parents, who sought medical attention for her friend. This led to the diagnosis of early-stage leukaemia, allowing him to receive timely treatment. Reuniting with her friend this year, she was thrilled to find him healthy and thriving.

After completing her PhD in biochemistry last year, Cocadiz realised that while she did not want to become a doctor, she still desired to contribute to the fight against cancer. “Everything just kind of fell into place, and I am really glad I ended up in cancer research,” she reflected.

Cocadiz is grateful for the grant from the Cancer Society, recognising its significance not only for her current research but also for her budding career in the field. As she continues her work, the potential impact of her innovative device on early cancer detection could change the landscape of cancer diagnostics, offering hope for more effective treatments in the future.

The team focuses on bringing trustworthy and up-to-date news from New Zealand. With a clear commitment to quality journalism, they cover what truly matters.

Trending

Copyright © All rights reserved. This website offers general news and educational content for informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the information provided. The content should not be considered professional advice of any kind. Readers are encouraged to verify facts and consult relevant experts when necessary. We are not responsible for any loss or inconvenience resulting from the use of the information on this site.